Bergkvist Karin, Winterling Jeanette, Johansson Eva, Johansson Unn-Britt, Svahn Britt-Marie, Remberger Mats, Mattsson Jonas, Larsen Joacim
Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden,
Support Care Cancer. 2015 May;23(5):1273-83. doi: 10.1007/s00520-014-2476-9. Epub 2014 Oct 17.
Earlier studies have shown that home care during the neutropenic phase after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is medically safe, with positive outcomes. However, there have been few results on long-term outcomes after home care. The aims of this study were to compare general health, symptom occurrence, and self-efficacy in adult survivors who received either home care or hospital care during the early neutropenic phase after allo-HSCT and to investigate whether demographic or medical variables were associated with general health or symptom occurrence in this patient population.
In a cross-sectional survey, 117 patients (hospital care: n = 78; home care: n = 39) rated their general health (SF-36), symptom occurrence (SFID-SCT, HADS), and self-efficacy (GSE) at a median of 5 (1-11) years post-HSCT.
No differences were found regarding general health, symptom occurrence, or self-efficacy between groups. The majority of patients in both hospital care (77 %) and home care (78 %) rated their general health as "good" with a median of 14 (0-36) current symptoms. Symptoms of fatigue and sexual problems were among the most common. Poor general health was associated with acute graft-versus-host disease (GVHD), low self-efficacy, and cord blood stem cells. A high symptom occurrence was associated with female gender, acute GVHD, and low self-efficacy.
No long-term differences in general health and symptom occurrence were observed between home care and hospital care. Thus, home care is an alternative treatment method for patients who for various reasons prefer this treatment option. We therefore encourage other centers to offer home care to patients.
早期研究表明,异基因造血干细胞移植(allo-HSCT)后中性粒细胞减少期的居家护理在医学上是安全的,且效果良好。然而,关于居家护理后的长期结果的研究结果较少。本研究的目的是比较allo-HSCT后早期中性粒细胞减少期接受居家护理或住院护理的成年幸存者的总体健康状况、症状发生情况和自我效能感,并调查在该患者群体中人口统计学或医学变量是否与总体健康状况或症状发生有关。
在一项横断面调查中,117名患者(住院护理:n = 78;居家护理:n = 39)在HSCT后中位5(1 - 11)年时对其总体健康状况(SF-36)、症状发生情况(SFID-SCT,HADS)和自我效能感(GSE)进行了评分。
两组在总体健康状况、症状发生情况或自我效能感方面未发现差异。住院护理组(77%)和居家护理组(78%)的大多数患者将其总体健康状况评为“良好”,当前症状中位数为14(0 - 36)。疲劳和性问题症状是最常见的症状之一。总体健康状况不佳与急性移植物抗宿主病(GVHD)、自我效能感低和脐血干细胞有关。症状发生率高与女性、急性GVHD和自我效能感低有关。
居家护理和住院护理在总体健康状况和症状发生情况方面未观察到长期差异。因此,对于因各种原因更喜欢这种治疗选择的患者,居家护理是一种替代治疗方法。因此,我们鼓励其他中心为患者提供居家护理。